Clinical efficacy of mechanical bacterial lysate in the prevention of infectious exacerbations of chronic obstructive pulmonary disease

Cover Page

Cite item

Full Text

Abstract

Aim. To evaluate the efficacy of mechanical bacterial lysate on the prevention of infectious exacerbations of chronic obstructive pulmonary disease in patients with frequent exacerbations.

Materials and methods. The study included patients (n=60) with frequent exacerbations of COPD (groups C and D according to the GOLD classification). All COPD patients were divided into two groups by blind method. The first group (n=30) received conventional therapy for COPD plus MBL (the course included 3 cycles of 10 days’ therapy with 20-day intervals between them). The second group of patients (control, n=30) received conventional therapy for COPD without MBL.We evaluated the severity of symptoms, frequency of recurrence of COPD exacerbations, readmissions, need for emergency care and changes in basic therapy of COPD. Evaluations were done on 10 days, 1, 3 and 6 months from the start of the study.

Results. Adding of MBL to the therapy list of COPD resulted in a significant decrease of biomarkers of systemic inflammation and sputum purulence during compared to the control group. After 6 months of observation MBL group demonstrated statistically significant improvement of respiratory function, decrease in frequency of COPD exacerbations, needs for emergency medical service, reduced changes in basic therapy and hospitalization for exacerbation of COPD. Therapy with MBL showed a high degree of safety and low incidence of adverse events.

Conclusion. The results of the study indicate that MBL may be used for the prevention of severe infectious exacerbations of COPD.

About the authors

S. N. Avdeev

Sechenov First Moscow State Medical University (Sechenov University); Scientific Research Institute of Pulmonology

Email: galia32@yandex.ru
ORCID iD: 0000-0002-5999-2150

чл.-кор. РАН, д.м.н., проф., зав. каф. пульмонологии; рук. клинического отд.

Russian Federation, Moscow

G. S. Nuralieva

Sechenov First Moscow State Medical University (Sechenov University); Scientific Research Institute of Pulmonology

Author for correspondence.
Email: galia32@yandex.ru
ORCID iD: 0000-0002-4726-4906

к.м.н., доц. каф. пульмонологии; науч. сотр. лаб. интенсивной терапии и дыхательной недостаточности 

Russian Federation, Moscow

V. V. Gainitdinova

Sechenov First Moscow State Medical University (Sechenov University)

Email: galia32@yandex.ru

д.м.н., проф. каф. пульмонологии

Russian Federation, Moscow

G. E. Baimakanova

Loginov Moscow Clinical Scientific Center

Email: galia32@yandex.ru
ORCID iD: 0000-0001-8198-9313

д.м.н., зав. отд. пульмонологии

Russian Federation, Moscow

A. K. So

Military Medical Academy

Email: galia32@yandex.ru
ORCID iD: 0000-0002-0112-9485

ассистент каф. пульмонологии Военно-медицинской академии

Myanmar, Mingladon

Z. M. Merzhoeva

Sechenov First Moscow State Medical University (Sechenov University); Scientific Research Institute of Pulmonology

Email: galia32@yandex.ru
ORCID iD: 0000-0002-3174-5000

ассистент каф. пульмонологии; науч. сотр. лаб. интенсивной терапии и дыхательной недостаточности 

Russian Federation, Moscow

References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2019. www.goldcopd.org/
  2. Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению ХОБЛ: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13-20 [Aysanov ZR, Avdeev SN, Arkhipov VV, et al. National clinical guidelines for the diagnosis and treatment of COPD: an algorithm for making clinical decisions. Pulmonology. 2017;27(1):13-20 (In Russ.)]. doi: 10.18093/0869-0189-2017-27-1-13-20
  3. Авдеев С.Н., Трушенко Н.В., Гайнитдинова В.В. и др. Лечение обострений хронической обструктивной болезни легких. Терапевтический архив. 2018;90(12):68-75 [Avdeev SN, Trushenko NV, Gainitdinova VV, et al. Treatment of exacerbations of chronic obstructive pulmonary disease. Therapeutic Archive. 2018;90(12):68-75 (In Russ.)]. doi: 10.26442/00403660.2018.12.000011
  4. Harper K, Armelagos G. The Changing Disease Scape in the Third Epidemiological Transition. Int J Environmental Res Public Health. 2010;7(2):675-97. doi: 10.3390/ijerph7020675
  5. Кривопалов А.А., Рязанцев С.В., Шаталов В.А. Новые возможности терапии и профилактики осложнений инфекционно-воспалительных заболеваний верхних дыхательных путей. Медицинский совет. 2016;18:24-32 [Krivopalov AA, Ryazantsev SV, Shatalov VA. New possibilities of therapy and prevention of complications of infectious and inflammatory diseases of the upper respiratory tract. Medical advice. 2016;18:24-32 (In Russ.)]. doi: 10.21518/2079-701X-2016-18-34-37
  6. Волков А.Г., Трофименко С.Л. Клинические проявления вторичного иммунодефицита при заболеваниях ЛОР-органов. М., 2008 [Volkov AG, Trofimenko SL. Clinical manifestations of secondary immunodeficiency in diseases of ENT organs. Moscow, 2008 (In Russ.)].
  7. Coley W. Contribution to the knowledge of sarcoma. Ann Surg. 1991;14:199-220.
  8. Seneca H. Urease activity of sonic lysates of pathogenic bacteria. Lancet. 1961;277(7187):1166-7.
  9. Hoffmann J, Hetru C. Insect defensins: inducible antibacterial peptides. Immunology Today. 1992;13(10):411-5. doi: 10.1016/0167-5699(92)90092-L
  10. Mahler DA, Rosiello RA, Harver A, et al. Comparison of clinical dyspnea ratings and psychophysical measurements on respiratory sensation in obstructive airway disease. Am Rev Respir Dis. 1987;135:1229-33. doi: 10.1164/arrd.1987.135.6.1229
  11. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-81.
  12. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648-54. doi: 10.1183/ 09031936.00102509
  13. Leidy NK, Rennard S, Schmier J, et al. The breathlessness, cough, and sputum scale. The development of empirically based guidelines for interpretation. Chest. 2002;124:2182–91. doi: 10.1378/chest.124.6.2182
  14. Logan JI. The TG system for bedside recording of sputum colour. Ulster Med J. 2006;75:228-30. doi: 10.1080 / 02813430902759663
  15. Cazzola M, Capuano A, Rogliani P, Matera G. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol. 2012;12:300-8. doi: 10.1016/j.coph.2012.01.019
  16. Braido F, Tarantini F, Ghiglione V, et al. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J COPD. 2007;2(3):335-45.
  17. Debbas N, Derenne JP. Preventive effects of an immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung. 1990;168(Suppl.):737-40. doi: 10,1007/bf02718202
  18. Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med. 1997;156(6):1719-24. doi: 10,1164/ajrccm.156.6.9612096
  19. Cogo R, Ramponi A, Scivoletto G, Rippoli R. Prophylaxis for acute exacerbations of chronic bronchitis using an antibacterial sublingual vaccine obtained through mechanical lysis: a clinical and pharmacoeconomic study. Acta BioMedica. 2003;74;81-7.
  20. Cazzola M. A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD. A double-blind, randomized, placebo-controlled trial. Trends Med. 2006;6(3):199-207.
  21. Cazzola M, Noschese P, Di Perna F. Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. Ther Adv Respir Dis. 2009;3:59-63. doi: 10.1177/1753465809104677

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The degree of decrease in the degree of purulence of sputum in patients with COPD during treatment.

Download (13KB)
Indexing metadata
3. Fig. 2. Dynamics of cough and sputum production according to BCSS in patients with COPD on the background of treatment.

Download (13KB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies